Evofem Biosciences (EVFM)
(Delayed Data from OTC)
$0.01 USD
0.00 (1.02%)
Updated Jul 12, 2024 01:41 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
EVFM 0.01 0.00(1.02%)
Will EVFM be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for EVFM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EVFM
Why Endo (ENDP) Stock Wilted After its Surge on Tuesday?
EVFM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for EVFM
Evofem gains on new U.S. patent covering Phexxi composition of matter
EVFM Stock Earnings: Evofem Biosciences Reported Results for Q1 2024
Evofem Biosciences GAAP EPS of -$0.16, revenue of $3.6M
Evofem Biosciences: Contractual Agreements Initiated and Terminated